TokenPost·
AstraZeneca Says Experimental Stomach Cancer Drug Doubled Survival
The company identified sonesitatug vedotin as the experimental treatment in a late-stage study.
More news
- TokenPostStansbury Pledges to Examine Trump’s Cryptocurrency Earnings
- TokenPost2025 Chip Revenue Estimate Ranks SK hynix Ahead of Intel
- TokenPostGoldman Sachs Sees CoreWeave Debt Need Fall With Longer GPU Life
- The DefiantHow a DAO Vote Becomes a Treasury Transfer
- The DefiantHow to Check a Software Wallet—and What the Checks Cannot Prove
- TokenPostBTIG Strategist Sees Post-Midterm Stock Risk as Credit Weakens